U.S. Patent & Trademark Office (USPTO)

[Image courtesy of HeartBeam]HeartBeam (Nasaq:BEAT) announced today that it received a key patent relating to AI capabilities for its AIMIGo system.

The U.S. Patent and Trademark Office (USPTO) issued the allowance for a patent titled “Hand Held Device for Automatic Cardiac Risk and Diagnostic Assessment.” The patent describes a system that combines recorded cardiac signals from AIMIGo with the patient’s symptoms and cardiac risk factors. Together, this calculates a cardiac risk score to provide simplified diagnostic information and actionable instructions.

Santa Clara, California-based HeartBeam said this aims to replicate the decision-making process of a physician assessing cardiac symptoms. However, with AIMIGo, it occurs remotely and in an automated manner.

HeartBeam developed AIMIGo as a personal, portable vector electrocardiogram (VECG) system. It assists patients and clinicians in assessing cardiac symptoms. It utilizes a reusable, credit card-…

HeartBeam (Nasdaq:BEAT) announced today that the U.S. Patent and Trademark Office issued a patent for its 12-lead electrocardiogram (ECG) patch.

Santa Clara, California-based HeartBeam designed its ECG patch monitor for detecting acute coronary syndrome (ACS) and cardiac arrhythmia.

The company said in a news release that the granted patent builds on its portfolio enabling 12-lead ECG diagnostics outside the medical setting. HeartBeam’s ECG can aid physicians in arrhythmia detection and ACS diagnosis that includes heart attack and angina.

“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and founder Branislav Vajdic. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy con…